Investigational drug · Phase 3
prolgolimab
Also called: BCD-100, Forteca
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Melanoma, Melanoma (Skin), Melanoma Stage III.
Phase 3Last checked: Nov 19, 2026Latest source record: Feb 27, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
5
Any phase or sponsor naming "prolgolimab"
First trial start
2022
Aug 2, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "prolgolimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Melanoma
- Melanoma (Skin)
- Melanoma Stage III
- Melanoma Stage IV
- Melanoma Unresectable
- Melanoma Metastatic
- Melanoma Advanced
Approved drugs for the same conditions: Melanoma · Oncology · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "prolgolimab" as an intervention, largest first.
- A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin MelanomaPivotal-lookingActive, not recruiting
BiocadIndustry
NCT05751928 · 411 participants · Start Apr 5, 2023 · Primary completion Jan 2027
Drug: BCD-217; anti-PD1 · For: Melanoma Stage III; Melanoma (Skin)
Sites: Lesnoy, Belarus; Minsk, Belarus; Mogilev, Belarus · 36 sites in all
- A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic MelanomaPivotal-lookingActive, not recruiting
BiocadIndustry
NCT05732805 · 270 participants (planned) · Start Aug 2, 2022 · Primary completion Jun 20, 2024
Drug: BCD-217; BCD-100 and 1 more · For: Melanoma; Melanoma (Skin); Melanoma Stage III and 4 more
Sites: Babruysk, Belarus; Brest, Belarus; Grodno, Belarus · 63 sites in all
- Prolgolimab 250 mg Q3W in Patients With Unresectable or Metastatic MelanomaPivotal-lookingStatus unknown
BiocadIndustry
NCT05783882 · 114 participants · Start Feb 1, 2022 · Primary completion Jun 2023
Drug: Prolgolimab · For: Unresectable or Metastatic Melanoma
Sites: Arkhangelsk, Russia; Chelyabinsk, Russia; Moscow, Russia · 6 sites in all
Blokhin's Russian Cancer Research CenterAcademic, hospital or other
NCT06428487 · 30 participants · Start Mar 31, 2022 · Primary completion Dec 31, 2024
Drug: Prolgolimab · For: Colorectal Cancer
Sites: Moscow, Russia
- Prolgolimab Monotherapy or in Combination With Bendamustine for r/r Classical Hodgkin LymphomaStatus unknown
St. Petersburg State Pavlov Medical UniversityAcademic, hospital or other
NCT05757466 · 30 participants (planned) · Start Apr 19, 2023 · Primary completion Mar 10, 2024
Drug: Prolgolimab; Combination with prolgolimab and bendamustine · For: Hodgkin Lymphoma
Sites: Saint Petersburg, Russia · 2 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Efficacy of immune checkpoint inhibitors in the first line therapy of non-squamous non-small cell lung cancer: A systematic review and network meta-analysis.
Fedyanin M, Zhukov N, Moiseenko F, et al. · Crit Rev Oncol Hematol 2026
- [Morphological features of immune-related cutaneous adverse events associated with anti-PD-1/PD-L1 cancer immunotherapy].
Syryseva AY, Shatokhina EA, Pokataev IA, et al. · Arkh Patol 2026
- Neoadjuvant Immunotherapy With Prolgolimab in Patients With Locally Advanced Microsatellite Instability/Defective Mismatch Repair Colorectal Cancer.
Kuznetsova O, Zagidullina A, Drobot N, et al. · JCO Precis Oncol 2025
- Corrigendum to "Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial" [Eur J Cancer. 227 (2025) 115674].
Demidov L, Samoylenko I, Kharkevich G, et al. · Eur J Cancer 2025
- Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial.
Demidov L, Samoylenko I, Kharkevich G, et al. · Eur J Cancer 2025
- Baseline Radiomics as a Prognostic Tool for Clinical Benefit from Immune Checkpoint Inhibition in Inoperable NSCLC Without Activating Mutations.
Moiseenko F, Radulovic M, Tsvetkova N, et al. · Cancers (Basel) 2025
Also in development for Melanoma
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- Intismeran autogeneV940, mRNA-4157Phase 310 trials
Merck & Co. · Non-small Cell Lung Cancer, Melanoma, Bladder Cancer
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- IBI363Phase 37 trials
Innovent Biologics (Suzhou) Co. Ltd. · Melanoma, Colorectal Cancer, Resectable Stage II-III Non-small Cell Lung Cancer
- OH2Phase 36 trials
Binhui Biopharmaceutical Co., Ltd. · Melanoma, Solid Tumor, Gastrointestinal Cancer
- PucotenlimabHX008Phase 36 trials
Lepu Biopharma Co., Ltd. · Head and Neck Squamous Cell Carcinoma, Melanoma, Hepatocellular Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.